Inventor · disambiguated record
Andrew Dibble
Also filed as: DIBBLE ANDREW
6 granted patents·5 pending applications·8 citations·filing 2013–2025
78Inventor score
Top patents by PatentIndex Score
11 records- 0189US10174318B2Antisense oligonucleotide compositionsIONIS PHARMACEUTICALS INC·Filed 2016·Granted Jan 8, 2019·3 cites·20 claims
- 0286US11634711B2Methods and compositions for modulating apolipoprotein (a) expressionIONIS PHARMACEUTICALS INC·Filed 2020·Granted Apr 25, 2023·1 cites·20 claims
- 0385US9574193B2Methods and compositions for modulating apolipoprotein (a) expressionIONIS PHARMACEUTICALS INC·Filed 2014·Granted Feb 21, 2017·2 cites·25 claims
- 0484US10478448B2Methods and compositions for modulating apolipoprotein (a) expressionIONIS PHARMACEUTICALS INC·Filed 2017·Granted Nov 19, 2019·1 cites·25 claims
- 0583US2024067964A1Methods and compositions for modulating apolipoprotein (a) expressionIONIS PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 0681US9884072B2Methods and compositions for modulating apolipoprotein (a) expressionIONIS PHARMACEUTICALS INC·Filed 2017·Granted Feb 6, 2018·1 cites·23 claims
- 0778US2025339457A1Methods and compositions for modulating apolipoprotein (a) expressionIONIS PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 0874US2020276224A1Methods and compositions for modulating apolipoprotein (a) expressionIONIS PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 0973US11859180B2Antisense oligonucleotide compositionsIONIS PHARMACEUTICALS INC·Filed 2020·Granted Jan 2, 2024·0 cites·20 claims
- 1070US2019316123A1Antisense oligonucleotide compositionsIONIS PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 1164US2016002624A1Antisense oligonucleotide compositionsISIS PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Andrew Dibble files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →